US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Observe Medical ASA: New share capital registered

Oslo, 17 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final results of the subsequent offering in the Company and the waiver of the condition for completion of the share capital increase of NOK 10,630,629.88, through the issuance of 40,887,038 new shares to Navamedic ASA, at a subscription price of 0.40 per share, in connection with the conversion by Navamedic ASA of a loan amount of NOK 16,354,815.20 under a loan from Navamedic ASA to the Company (the "Loan Conversion")

Observe Medical ASA: Key information relating to share reverse split

Date on which the corporate action was made public: 17 December 2024. Reverse split ratio: 15 old shares give 1 new share. Last day including right: To be decided by the board of directors (subject to approval by the extraordinary general meeting). Ex-date: To be decided by the board of directors (subject to approval by the extraordinary general meeting). Record date: To be decided by the board of directors (subject to approval by the extraordinary general meeting). Date of approval: 7 January 2025. Other information (optional): Reference is made to the notice of the

Observe Medical ASA: Notice of extraordinary general meeting on 7 January 2025 in connection with reverse share split

Oslo, 17 December 2024 An extraordinary general meeting of Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) will be held on 7 January 2025 at 10:00 (CET). The notice of the extraordinary general meeting, including agenda, proposed resolutions, registration form, a form of proxy and other relevant documents, is enclosed hereto. The agenda includes a proposal for a consolidation of the Company's shares (reverse share split), in the ratio 15:1, to meet the Oslo Stock Exchange's requirement of a minimum market value of NOK 1 per share. To facilitate the share

Observe Medical ASA: Mandatory notification of trade by close associates to primary insider

Oslo, 13 December 2024: Observe Medical ASA (the "Company") has been informed that Seed Capital AS, a company owned 50% by Eskild Endrerud board member and primary insider in the Company, has purchased 178,268  shares in the Company as further specified in the attached notification form. Following the purchase, Seed Capital AS holds 242,335 shares in the Company. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Observe Medical ASA: Registration of new share capital

Oslo, 13 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 5 December 2024 regarding the final result of the subsequent offering in the Company, where a total of 2,303,933 new shares were subscribed and allocated at a subscription price of NOK 0.40 per share.    The share capital increase pertaining to the subsequent offering has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company's registered share capital is NOK 64,477,175.62 divided into

Observe Medical ASA: Mandatory notification of trade by primary insider and disclosure of shareholding

Oslo, 12 December 2024: Observe Medical ASA (the "Company") has been informed that Rune Nystad, CDO and primary insider in the Company, has sold 1,144,962 shares in the Company to his wholly owned investment company US Holding AS as part of a reorganization of his shareholding.  Following this, 1,662,483 of the shares in Observe Medical ASA is still controlled by Rune Nystad. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

OBSERVE MEDICAL ASA: Mandatory notification of trade – grant of share options to primary insider

Oslo, 12 December 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 500,000 share options to primary insider and CFO of the Company, Johan Fagerli. Each share option gives the right to purchase one share in the Company. The share options will vest over a period of two years. 1/3 of the share options vested today on the award date, 1/3 of the share options will vest on the first anniversary of the award date and 1/3 of the share options will vest on the second anniversary of the award date. The share options will be exercisable during

Observe Medical ASA: Notification of transaction by close associate to primary insider and disclosure of large shareholding

Oslo, 5 December 2024: Reference is made to the stock announcement published by Observe Medical ASA (the "Observe Medical") on 5 December 2024 regarding the final result of the subsequent offering and the partial conversion to shares of certain loans from Navamedic ASA ("Navamedic") to Observe Medical. Navamedic currently holds 4,222,727 shares in Observe Medical, equal to approx. 1.72% of the current shares and votes in Observe Medical. Following the issuance and registration of the shares in both the subsequent offering and the shares to be issued to Navamedic in connection with the

Observe Medical ASA: Final result of the subsequent offering and allocation of shares; Updated amendments of loans from Navamedic ASA to be implemented including partial conversion to shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 5 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 19 November 2024, regarding the launch of a subsequent offering of up to 32,500,000 new shares ("Offer Shares") in

OBSERVE MEDICAL ASA: Preliminary results of the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 4 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 19 November 2024 regarding the launch of a subsequent offering of up to 32,500,000 new shares ("Offer Shares") in

OBSERVE MEDICAL ASA: Last day of the subscription period in the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 4 December 2024 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 19 November 2024, regarding the launch of a subsequent offering of up to 32,500,000 new shares ("Offer Shares") in

Observe Medical ASA: Mandatory notification of trade by primary insider

Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed that Jørgen Mann, CEO and primary insider in the Company, has today purchased 100,000 shares in the Company as further specified in the attached notification form. Following the purchase, Jørgen Mann holds 600,000 shares in the Company. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Observe Medical ASA: Mandatory notification of trades by primary insider

Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed that Terje Bakken, chairman of the board and primary insider in the Company, has today purchased 100,000 shares in the Company as further specified in the attached notification form. Following the purchase Terje Bakken holds 100,000 shares in the Company. In addition, Terje Bakken holds 1,250,000 shares through Kikinn Invest AS. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

OBSERVE MEDICAL ASA: Approval and publication of prospectus, listing of the tranche 2 private placement shares and launch of subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 19 November 2024 Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 24 June 2024, regarding the successful placement of a private placement in the Company raising

Observe Medical ASA: Agreement reached with Convatec to defer payments by 12 months

Oslo, 19 November, 2024 – Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company" or "Observe Medical") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its working capital situation. The Company has today, through its subsidiary Observe Medical AS, reached an agreement with Convatec/Unomedical to defer all outstanding payments of consideration pursuant to the asset transfer agreement with Convatec/Unomedical for the

OBSERVE MEDICAL ASA: Resolutions to increase the share capital in connection with subsequent offering and conditional loan conversion

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 18 November 2024 Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 24 June 2024, regarding the successful placement of a private placement in the Company raising

Observe Medical ASA: Amendments to loan agreements with Navamedic ASA

Oslo, 15 November 2024: Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 12 November 2024, in which it inter alia was stated that the Company is in dialogue with strategic and financial partners to evaluate options to further strengthen its working capital situation. The Company has (as borrower) entered into two subordinated loan agreements with Navamedic ASA ("Navamedic") as lender for (i) a loan with an outstanding principal amount of NOK 32,000,000 plus accrued interest, entered into on 27 September 2019 ("Loan I") and (ii) a

Observe Medical – DOC (Declaration of Conformity) signed for UnoMeter[TM ]Safeti[TM] Plus and subscription form for equity investment received from industrial partner

Oslo, November 12[th], 2024 - Observe Medical ("the Company" or "Observe Medical") has today signed the DOC (Declaration of Conformity). This marks the final step for the establishment of a high-volume manufacturing platform for the UnoMeter™ product portfolio, consisting of UnoMeter™ 500 and UnoMeter™ Safeti™ Plus. The DOC is the final regulatory documentation that needs to be approved for the Observe Medical group to be able to accept and receive orders for UnoMeter™ Safeti™ Plus from customers and also accept other relevant commercial and financial commitments related thereto. The

OBSERVE MEDICAL ASA: Mandatory notification of trade – grant of share options to primary insider

Oslo, 26 August 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 1,000,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to purchase one share in the Company. The share options will vest over a period of two years. 1/3 of the share options vested today on the award date, 1/3 of the share options will vest on the first anniversary of the award date and 1/3 of the share options will vest on the second anniversary of the award date. The share options will be exercisable during

OBSERVE MEDICAL ASA: First half year report 2024

Oslo, August 26, 2024 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2024. Business update In the first half of 2024, Observe Medical achieved growth and market expansion of the UnoMeter™ portfolio. Observe Medical has achieved a major milestone with the early commercial launch of the UnoMeter™ Safeti Plus, marking significant strategic and commercial progress. This success highlights the effective collaboration between our product development team and external manufacturing partner. The launch underscores our commitment to

Observe Medical – First order from South America

Oslo, August 22, 2024 - Observe Medical ("the Company" or "Observe Medical") has received its first order of UnoMeter 500 products from a distributor in South America. This initial order represents a significant step towards expanding our footprint in a region that holds historical importance for the UnoMeter product line. This marks a significant milestone as we now have established sales networks across Europe, the Middle East, Asia, and South America, closely mirroring the extensive geographic reach previously achieved by Convatec. Jørgen Mann, CEO of Observe Medical, commented, "

Invitation to Observe Medical ASA's first half year 2024 presentation and Q&A

Oslo, August 19, 2024 - Observe Medical ("the Company" or "Observe Medical") will release its results for the first half year 2024 on Monday, 26 Augsut 2024. The presentation will be published on NewsWeb and the Company's website at 07:00 CET on the same day. The Company will host a presentation and Q&A session at 10:00 CET on the same day. Personal attendance is welcomed at Carnegie's offices at Aker Brygge, Fjordalleen 16. The session will also be streamed via webcast. To register and follow the presentation online, please copy and paste the following link into your browser, click

Jørgen Mann appointed permanent CEO of Observe Medical

Oslo, August 13, 2024 - Observe Medical ASA (the "Company" or "Observe Medical") announces the appointment of Jørgen Mann as its permanent Chief Executive Officer (“CEO”). Having served as interim CEO since February 2024, Mr. Mann has proven his leadership capabilities and deep insight into the Company's strategic operations. The board is fully confident in his ability to steer Observe Medical into its next phase, focusing on commercial milestones, growth, and innovation. His leadership is expected to be crucial as the Company moves forward with its ambitious goals in the healthcare

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe